Background: Advances in multiple myeloma (MM) treatment enhance survival; however, they may impair QOL.The present study aimed to evaluate treatment-related Health-Related Quality of Life (HRQoL) scores among patients undergoing treatment with novel agents. Methods: This six-month prospective study was conducted among adult patients with ≥18 years who newly diagnosed with MM (NDMM)of either sex. Demographic, co-morbidities, laboratory investigations, and distribution of Bense-Jones protein were recorded at baseline. Study outcomes were recorded as a response to self-reported European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30 version 3.0) at baseline, 4thand 6thmonth follow-up. Results: Total 31 patients were included withmean age of 60.29 years. Hypertension was the most common comorbidity observed in 48.39% of patients, followed by chronic obstructive pulmonary disease in 16.13%. Significant (p<0.001) improvement was observed in mean global health statusfrom baseline (48.66) to 6th months (63.39).Additionally, mean functional scales including physical (40.65 vs. 58.10), role (46.77 vs. 66.67), emotional (61.02 vs. 77.78), and social (48.39 vs. 59.52) along with mean symptom scales including fatigue (51.61 vs. 39.70), pain (59.14 vs. 39.51), and dyspnea (41.93 vs. 21.43), were significantly improved from baseline to 6th month with p<0.001 after receiving treatment. Overall summary score of both the scales showed significant improvement from baseline to 4th and 6th months with p<0.001. Conclusion: The mean score of HRQoL significantly improved with the treatment of MMmaking it an important measure of QoL among patients with MM.